Fund Overlap
See which holdings any two equity ETFs have in common, along with top differences in exposure.
For overlap across multiple ETFs use Portfolio Builder
OVERLAP
23%
OVERLAP
BY WEIGHT
BY WEIGHT
10
# OF OVERLAPPING HOLDINGS
IDNA
46
HOLDINGS
25%
ALSO IN CANC
CANC
48
HOLDINGS
21%
ALSO IN IDNA
SECTOR DRIFT (IDNA minus CANC)
OVERLAPPING HOLDINGS
Top 5 only shown here. Please log-in or sign up for a Basic (Free) membership to view the complete list.
| Company | Weight in IDNA |
Weight in CANC |
Overlap | |
|---|---|---|---|---|
 |
EXELIXIS INC | 4.1% | 4.1% | 4.1% |
 |
ASTRAZENECA PLC | 3.9% | 4.1% | 3.9% |
|
REVOLUTION MEDICINES, INC. | 3.7% | 4.9% | 3.7% |
|
ARCELLX, INC. | 3.9% | 3.1% | 3.1% |
|
MERCK & CO. INC. | 4.1% | 2.5% | 2.5% |
IDNA Overweight Relative to CANC
|
TWIST BIOSCIENCE CORP. | 4.6% |
 |
TAKEDA PHARMACEUTICAL CO LTD | 4.1% |
|
SPRINGWORKS THERAPEUTICS, INC. | 4.1% |
 |
ROCHE HOLDING LTD | 4.1% |
|
INCYTE CORP | 4.1% |
|
MODERNA, INC. | 4.0% |
 |
BIONTECH SE SPONSORED ADR | 4.0% |
 |
SANOFI-AVENTIS | 3.9% |
|
GSK PLC | 3.8% |
 |
GENMAB A/S | 3.8% |
IDNA Underweight Relative to CANC
|
ROCHE HOLDINGS LTD-SPONS ADR | -5.3% |
|
ELI LILLY & CO | -5.2% |
|
BRIDGEBIO PHARMA, INC. | -4.9% |
|
NOVARTIS AG | -4.4% |
 |
MERUS N.V. | -3.8% |
|
GENMAB A/S SPONSORED ADR | -3.7% |
|
NUVALENT, INC. CLASS A | -3.5% |
|
BRISTOL-MYERS SQUIBB CO | -3.5% |
|
AMGEN INC | -3.3% |
|
SUMMIT THERAPEUTICS INC | -3.1% |